Private limited company · Oslo
GENTILI PHARMA AS
ActiveManufacture of pharmaceutical preparations (21.200)
The life line 2023–2026
Operating revenue per year, with recorded events above. As a table
Operating revenue 2025: NOK 122.3m.
Sources: the Register of Company Accounts (company accounts), fetched 1 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.
In brief
GENTILI PHARMA AS is a private limited company in Oslo, founded in 2023, in the industry manufacture of pharmaceutical preparations. The chair of the board is Angelo Pelliccioni. In 2025 the company had NOK 122.3m in operating revenue and a net profit of NOK 59.2m.
Put together by Intelligo from the sections below; each figure stands with its source where it belongs.
Overview
§ 01 Latest changes
4 changes, latest 8 Sep 2026
- Won a tender from Pohjois-Pohjanmaan hyvinvointialue
- Annual accounts filed 2024 → 2025
- Lost a tender: Läkemedel 2025 del 2
- Endring av styre
Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →
Overview
§ 02 Worth knowing
1 point
- OKEquity ratio 70.7%, above the industry median
Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate
Overview
§ 03 Key figures
Revenue NOK 122.3m in 2025
Revenue
NOK 122.3m
— from 2024
20232025
Operating profit
NOK 75.9m
+1,362,020.5% from 2024
20232025
Net profit
NOK 59.2m
+1,390,823.5% from 2024
20232025
Equity
NOK 59.3m
+106,279.0% from 2024
20232025
Demerger carried out 29 Jan 2024: the figures before and after are not the same business.
Source: the Register of Company Accounts, read 1 Nov 2026 · The full accounts →
Finances
§ 04 Where the money comes from and goes
Financial year 2025
Of every krone of operating revenue in 2025:
- Wages and social costs 6%
- Depreciation 1%
- Other operating costs 12%
- Not specified in the source 21%
- Left as operating result 60%
Source: the Register of Company Accounts via areg.no, read 15 Nov 2026
Finances
§ 05 Financial health
Equity ratio 70.7%
- GENTILI PHARMA AS, 2025
- Industry median, assumed: NOK 31.9m · 7.0% · 50.3%
Equity NOK 59.3m71% of the assets (NOK 83.9m)
Source: the Register of Company Accounts, read 1 Nov 2026. The median is derived by Intelligo from 28 companies in 21.200 Manufacture of pharmaceutical preparations, not stated by the source.
Finances
§ 06 Accounts
2 years, latest 2025
| NOK 1,000 | 2024–25 | 2025 | 2024 |
|---|---|---|---|
| Operating revenue | 122,346 | — | |
| Operating profit | 75,859 | −6 | |
| Profit before tax | 75,754 | −5 | |
| Net profit | 59,203 | −4 | |
| Total assets | 83,873 | 56 | |
| Equity | 59,299 | 56 | |
| Liabilities | 24,575 | 0 |
Source: the Register of Company Accounts, read 1 Nov 2026 · All 2 years →
Management and ownership
§ 07 Officers
3 officers now
- KPMG ASAuditor since 2023
- PWC TAX SERVICES ASAccountant
- Angelo PelliccioniChair of the board since 2025
Source: the Brønnøysund Register Centre, read 23 Oct 2026 · All 3 roles, former ones too →
Management and ownership
§ 08 Signature, procuration and authorisations
Styrets leder alene.
May sign for the company:
Styrets leder alene.
Procuration: none registered.
The signature is word for word from the register. Source: the Register of Business Enterprises, read 5 Oct 2026
Management and ownership
§ 09 Owners
None registered
No owners registered.The Tax Administration's shareholder register covers limited companies and has no owners for this business. Checked 15 Nov 2026.
Management and ownership
§ 10 Group
None registered
Not a group.No subsidiaries in the shareholder register, and no group accounts. Checked 15 Nov 2026.
Management and ownership
§ 11 Portfolio
None registered
No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.
Management and ownership
§ 12 Network
None registered
No connections.Nobody with a role here has roles in other companies. Checked 15 Nov 2026.
Events and registers
§ 13 Events
25 since 2023
Events per year
20232026
Since 2023: 23 announcements, 1 register change and 1 tender won. Most happened in 2023 and 2024.
Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 16 Nov 2026. Register changes are Intelligo's own observations. · All 25 events →
Events and registers
§ 14 Notices
23, latest 13 Nov 2025
- Styre
- Kapital
- Vedtektsdato
Source: The Brønnøysund Register Centre's announcements ↗, read 16 Nov 2026 · All 23 →
Events and registers
§ 15 Charges
Not fetched yet
Events and registers
§ 16 Other registers
Found in 3 of 7
- The Central Coordinating RegisterRegistered 1 Jun 2023
- VATRegistered
- The Register of Business EnterprisesRegistered 1 Jun 2023
- The Cleaning RegisterNot registered
- The Register of Staffing AgenciesNot registered
- Smiley scheme, the Norwegian Food Safety AuthorityNot registered
- The Financial Supervisory Authority's licence registerNot registered
Purpose: a. å produsere og handle med kjemiske og biologiske produkter for den farmasøytiske industrien, herunder innenfor medisinske spesialiteter, galeniske, dietetiske, ernæringsmessige og fytoterapeutiske produkter. b. å stifte, delta i, på hvilken som helst måte, samt administrere og føre tilsyn med, virksomheter og selskaper. c. å finansierevirksomheter og selskaper. d. å låne, låne ut og tilveiebringe midler, herunder ved utstedelse av obligasjoner, gjeldsbrev eller andre verdipapirer eller bevis på gjeld, samt å inngå avtaler i forbindelse med nevnte aktiviteter e. å yte råd og tjenester til virksomheter og selskaper som inngår i samme konsern som selskapet, samt til tredjeparter f. å gi garantier, forplikte selskapet, samt å pantsette selskapets eiendeler som sikkerhet for forpliktelser tilhørende andre virksomheter og selskaper som inngår i samme konsern som selskapet, samt på vegne av tredjeparter g. å erverve, avhende, administrer og utnytte fast eiendom, og andre eiendeler generelt h. å handle med valuta, verdipapirer og eiendeler generelt i. å utvikle og handle med patenter, varemerker, lisenser knowhow og andre immaterielle rettigheter j. å utføre alle aktiviteter av industriell, finansiell eller kommersiell art samt alt som står i naturlig forbindelse med det forannevnte, i sin videste forstand.
Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026
Market
§ 17 Tenders
2 tenders
- 2025
- 2026
- Won
- Lost
| Awarded | Contract | Buyer | Outcome |
|---|---|---|---|
| Sep 2026 | Lääkevalmisteet ja niihin rinnastettavat tuotteet hankintakaudelle 1.1.2026-31.12.2027 | Pohjois-Pohjanmaan hyvinvointialue | Won |
| Dec 2025 | Läkemedel 2025 del 2 | Region Skåne, Koncernstab inköp och ekonomistyrning | Lost |
Source: Doffin and TED, read 8 Sep 2026. · All 2 tenders →
Market
§ 18 Vacancies
None registered
No vacancies.No open ads at NAV. Checked 15 Nov 2026.
Market
§ 19 Competitors
Industry code 21.200
The companies most like it:
Compare themThe selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →
Last
§ 20 Questions and answers
5 questions
- What was the revenue in 2025?
NOK 122.3m in the company. § 06 - Who can sign for GENTILI PHARMA AS?
Styrets leder alene. § 08 - Who is the auditor?
KPMG AS, from 30 Oct 2023. § 07 - Where is GENTILI PHARMA AS based?
Dronningens gate 3, 0152 Oslo. - When was GENTILI PHARMA AS founded?
1 May 2023, registered in the Register of Business Enterprises 1 Jun 2023. § 16
The answers come from the sections linked to, with their sources.